Priothera Limited
Priothera is developing the orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies.
Priothera Limited has raised €30M across 1 funding round from 4 investors, most recently a Series A round in Oct 2020. Based in Dublin, Ireland; founded 2020; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€30M
€30,000,000
Funding rounds
1
Investors
4
distinct backers
Active since
2020-10
latest 2020-10
Funding by year
EUR raised per yearPriothera Limited — funding by year — interactive chart.
Data table
| Priothera Limited — funding by year | |
|---|---|
| 2020 | €30M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-10-14 | Series A | €30M | Earlybird Venture Capital,Fountain Healthcare Partners,HealthCap,Tekla Capital Management | View deal → |
Related news
Similar companies
same sector or country- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
- Wayflyer€2.1BIreland · E-commerce
- CMR Surgical€1.5BUK · Healthtech
- Roivant Sciences€1.1BSwitzerland · Healthtech
- Neko Health€924MSweden · Healthtech
Global coverage: FundingData